BMYMP - BridgeBio: Potential Based On Diverse Pipeline Targeting KRAS Mutations And Rare Diseases
- First patient dosed in phase 1/2 ADventure study which is using BBP-631 for the treatment of patients with congenital adrenal hyperplasia; results from the study expected 2nd half of 2022.
- An SHP2 inhibitor BBP-398 is being explored in combination with Amgen's LUMAKRAS, along with a few other combinations studies; in addition, next generation dual KRAS G12C inhibitor being developed.
- Development of a next generation KRAS G12C dual inhibitor provides further development into targeting RAS mutations.
- Results from a phase 2 study using BBP-418 in patients with limb-girdle muscular dystrophy type 2i reported as proof of concept; Phase 3 study expected to start in 2nd half of 2022.
For further details see:
BridgeBio: Potential Based On Diverse Pipeline Targeting KRAS Mutations And Rare Diseases